Terpenoid ID | TKC005454 | |
Cell line | 0 | |
Protein target | 65 | |
DiseaseNCIT | 0 | |
ORDO | 0 | |
ICD | 126 |
ID | Cell Line | Synonyms | Value | Unit | Type | NCIt | ORDO |
---|---|---|---|---|---|---|---|
TKC005454 | AGS | 10200.0 | nM | IC50 | C4004 | ||
TKC005454 | PBMC | 37400.0 | nM | IC50 | |||
TKC005454 | OVCAR-3 | Ovcar-3; OVCAR 3; OVCAR.3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR3; Ovcar3 | 9.0 | uM | CD50 | C105555 | |
TKC005454 | HepG2 | 10000.0 | nM | Potency | C3728 | Orphanet_449 | |
TKC005454 | HeLa | HELA; Hela; He La; He-La; HeLa-CCL2; Henrietta Lacks cells; Helacyton gartleri | 17.0 | uM | CD50 | C27677 | |
TKC005454 | MIA PaCa-2 | MIA-PaCa-2; MIA-PACA-2; MIA-Pa-Ca-2; MIA Paca2; MIA PaCa2; MiaPaCa-2; MIAPACA-2; MiaPaca.2; MiaPaCa2; Miapaca2; MIAPaCa2; MIAPACA2; Mia PACA 2; MIAPaCa-2; PaCa2; MiaPaCa | 5800.0 | nM | IC50 | C9120 | |
TKC005454 | Vero | VERO; VeroCCL81; Vero 81; Vero-81; Verda reno | 33380.0 | nM | CC50 | ||
TKC005454 | MDA-N | MDAN | 1611.0 | nM | GI50 | C3802 | |
TKC005454 | SN12C | SN-12C | 4365.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC005454 | NCI-H23 | NCI.H23; NCI H23; H-23; H23; NCIH23 | 1549.0 | nM | GI50 | C3512 | |
TKC005454 | ACHN | 3597.0 | nM | GI50 | C6975 | Orphanet_319298 | |
TKC005454 | UO-31 | UO.31; UO31; U031 | 4699.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC005454 | HOP-92 | HOP 92; HOP.92; HOP92; Hop92; Hopkins-92 | 40832.0 | nM | GI50 | C2926 | |
TKC005454 | HL-60 | HL 60; HL.60 HL60; Human Leukemia-60 | 2388.0 | nM | GI50 | C9154 | Orphanet_519 |
TKC005454 | DU-145 | DU-145; Du-145; DU 145; DU_145; DU.145; Duke University 145 | 1352.0 | nM | GI50 | C4863 | |
TKC005454 | SF-539 | SF-539; SF-539 BT; SF.539; SF 539 | 3350.0 | nM | GI50 | C3796 | Orphanet_251576 |
TKC005454 | Malme-3M | MALME-3M; MALME 3M; Malme-3 M; MALME.3M; Malme3M; MALME3M; Malme-3 Monolayer | 305.0 | nM | GI50 | C3224 | |
TKC005454 | SK-MEL-5 | SK-Mel-5; SK MEL 5; SK.MEL.5; SK-MEL5; SKMel-5; SKMEL-5; SKMEL5; SKMel5; SKmel5; AA-Mel | 382.0 | nM | GI50 | C3510 | |
TKC005454 | K562 | K562; K.562; K 562; KO; GM05372; GM05372E | 3606.0 | nM | GI50 | C9110 | Orphanet_521 |
TKC005454 | A498 | A498 | 18323.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC005454 | MOLT-4 | Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C; GM02219D | 4236.0 | nM | GI50 | C9142 | Orphanet_99861 |
TKC005454 | HOP-62 | HOP 62; Hop 62; HOP.62; HOP62; Hop62; Hopkins-62 | 3681.0 | nM | GI50 | C3512 | |
TKC005454 | U-251 | U-251 MG; U-251-MG; U-251_MG; U251-MG; U251MG; U-251; U251; U251n; U251N; 251 MG; 251MG; 251 MG(6) | 1995.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC005454 | NCI/ADR-RES | NCI/ADR-RES; NCI.ADR.RES; NCIADR.RES; NCI/ADRRES; NCIADRRES; ADR-RES; MCF-7/ADR; MCF-7/ADR-RES; MCF-7/AdrR; MCF-7/Adr; MCF-7/adr; MCF-7ADR; MCF7-ADR; MCF7ADR; OVCAR-8/ADR; OVCAR8/ADR | 2786.0 | nM | GI50 | C105555 | |
TKC005454 | OVCAR-5 | OVCAR 5; NIH:OVCAR-5; OVCAR.5; OVCAR5; Ovcar5; OVCA5 | 16069.0 | nM | GI50 | C105555 | |
TKC005454 | OVCAR-8 | OVCAR 8; NIH:OVCAR-8; OVCAR8; Ovcar8; OVCAR.8; OVCA8 | 2576.0 | nM | GI50 | C105555 | |
TKC005454 | SNB-19 | SNB.19; SNB19; Surgical Neurology Branch-19 | 2518.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC005454 | TK-10 | TK.10; TK 10; TK10 | 8185.0 | nM | GI50 | C4033 | Orphanet_319276 |
TKC005454 | SR | SR-786; SR786 | 3420.0 | nM | GI50 | C37193 | Orphanet_300895 |
TKC005454 | SW-620 | SW-620; SW 620; SW.620 | 1730.0 | nM | GI50 | C4349 | |
TKC005454 | NCI-H522 | NCI.H522; H522; H-522; NCI-522; NCI522; NCIH522 | 2009.0 | nM | GI50 | C3512 | |
TKC005454 | KM12 | KM-12; KM.12 | 2193.0 | nM | GI50 | C4910 | |
TKC005454 | M14 | M14-MEL; UCLA-SO-M14; UCLA SO M14; UCLA-SO-14; UCLASO-M14; Melanoma 14; M-14 | 1033.0 | nM | GI50 | C3802 | |
TKC005454 | NCI-H322M | NCI.H322M; H322M; H-322M; H-322m | 1644.0 | nM | GI50 | C2923 | |
TKC005454 | RPMI-8226 | RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson | 3311.0 | nM | GI50 | C3242 | Orphanet_29073 |
TKC005454 | OVCAR-4 | OVCAR 4; NIH:OVCAR-4; NIH:OVCAR4; OVCAR.4; OVCAR4; Ovcar4 | 12190.0 | nM | GI50 | C105555 | |
TKC005454 | LOX IMVI | LOX/IMVI; LOX IMVI; LOXIM-VI; LOXIMVI; LOX | 2518.0 | nM | GI50 | C3802 | |
TKC005454 | BT-549 | BT 549; BT.549; BT549 | 2109.0 | nM | GI50 | C4194 | |
TKC005454 | SK-MEL-2 | SK-Mel-2; SK-Mel 2; SK-mel-2; SK-MEL2; SK.MEL.2; SK Mel 2; SK MEL 2; SKMEL-2; SKMEL2; SKmel2; SK-ML2; SKml2 | 4246.0 | nM | GI50 | C3224 | |
TKC005454 | A549 | 1050.0 | nM | GI50 | C3512 | ||
TKC005454 | SNB-75 | SNB.75; SNB75; Surgical Neurology Branch-75 | 881.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC005454 | HCC 2998 | HCC-2998; HCC.2998; HCC 2998; Hamon Cancer Center 2998 | 2483.0 | nM | GI50 | C4349 | |
TKC005454 | HCT-15 | HCT-15; HCT.15; HCT15 | 1941.0 | nM | GI50 | C4349 | |
TKC005454 | HCT-116 | HCT-116; HCT.116; HCT_116; HCT116; HCT116wt; CoCL2 | 2965.0 | nM | GI50 | C4910 | |
TKC005454 | SF-268 | SF-268; SF.268; SF 268 | 1901.0 | nM | GI50 | C60781 | Orphanet_94 |
TKC005454 | EKVX | 4624.0 | nM | GI50 | C3512 | ||
TKC005454 | SK-OV-3 | SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3 | 11614.0 | nM | GI50 | C7978 | |
TKC005454 | PC-3 | PC3; PC.3 | 4932.0 | nM | GI50 | C4863 | |
TKC005454 | T47D | 9462.0 | nM | GI50 | C4194 | ||
TKC005454 | NCI-H460 | NCI.H460; H460; H-460; NCIH460; NCI-HUT-460; NCI-460 | 1633.0 | nM | GI50 | C4450 | |
TKC005454 | UACC-62 | UACC 62; UACC.62; UACC62; University of Arizona Cell Culture-62 | 2032.0 | nM | GI50 | C3224 | |
TKC005454 | MDA-MB-435 | MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435; MD Anderson-Metastatic Breast-435 | 1416.0 | nM | GI50 | C3802 | |
TKC005454 | CAKI-1 | CAL 1; Centre Antoine Lacassagne-1 | 8222.0 | nM | GI50 | C3224 | |
TKC005454 | SF-295 | SF-295; SF.295; SF 295 | 1679.0 | nM | GI50 | C3058 | Orphanet_360 |
TKC005454 | IGROV-1 | Igrov-1; IGROV 1; IGR-OV1; IGROV1; Igrov1; IGR.OV1; IGROV; OV1/P; OV1/p; OV1-P | 2710.0 | nM | GI50 | C7979 | Orphanet_454723 |
TKC005454 | Hs-578T | HS 578T; Hs-578T; HS-578T; Hs_578t; Hs-578-T; HS-578-T; Hs 578.T; HS578T; Hs578T; Hs578t; HS0578T; 578T; HS578; Hs578; Homo sapiens No. 578, tumor cells | 2291.0 | nM | GI50 | C4194 | |
TKC005454 | UACC-257 | UACC 257; UACC.257; UACC257; University of Arizona Cell Culture-257 | 1954.0 | nM | GI50 | C3224 | |
TKC005454 | 786-0 | 786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT | 3420.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC005454 | CCRF-CEM | CCRF/CEM; CCRFCEM; CCRF.CEM; CCRF CEM; CCRF; CEM; CEM-CCRF; CEM-CCRF (CAMR); CCRF/CEM/0; CEM/0; CEM-0; CCRF-CEM/S; GM03671; GM03671C | 4305.0 | nM | GI50 | C7953 | Orphanet_99861 |
TKC005454 | NCI-H226 | NCI.H226; NCI H226; H226; H-226; HUT-226; HUT 226; NCIH226 | 3243.0 | nM | GI50 | C45662 | Orphanet_50251 |
TKC005454 | HT-29 | HT 29; HT29 | 2183.0 | nM | GI50 | C4349 | |
TKC005454 | SK-MEL-28 | SK-Mel-28; SK.MEL.28; SK-MEL 28; SK MEL-28; SK MEL 28; SK Mel 28; SKMel-28; SKMEL-28; SK-MEL28; SK-Mel28; SK Mel28; SKMEL28; SKMel28; SKmel28; SKML-28; SK28; AU-Mel; P-36; P36 | 3192.0 | nM | GI50 | C3510 | |
TKC005454 | RXF 393 | RXF393L; RXF-393 L; RXF-393; RXF 393; RXF.393; RXF393; RXF 393NL | 6295.0 | nM | GI50 | C9385 | Orphanet_217071 |
TKC005454 | COLO 205 | Colo 205; CoLo 205; COLO-205; Colo-205; COLO.205; Colo205; COLO205; Co 205; Colorado 205 | 1148.0 | nM | GI50 | C4349 |
ID | Uniport | Pref_name | Gene name | value | unit | type |
---|---|---|---|---|---|---|
TKC005454 | P00352 | Retinal dehydrogenase 1 | ALDH1A1 | 10000 | nM | Potency |
TKC005454 | P10636 | Microtubule-associated protein tau | MAPT | 3548 | nM | Potency |
TKC005454 | P11473 | Vitamin D3 receptor | VDR | 7080 | nM | Potency |
TKC005454 | Q9NUW8 | Tyrosyl-DNA phosphodiesterase 1 | TDP1 | 12995 | nM | Potency |
TKC005454 | P18031 | Tyrosine-protein phosphatase non-receptor type 1 | PTPN1 | 33500 | nM | IC50 |
TKC005454 | P08575 | Receptor-type tyrosine-protein phosphatase C | PTPRC | 41400 | nM | IC50 |
TKC005454 | P17706 | Tyrosine-protein phosphatase non-receptor type 2 | PTPN2 | 55700 | nM | IC50 |
TKC005454 | P07943 | Aldo-keto reductase family 1 member B1 | Akr1b1 | 4786 | nM | IC50 |
TKC005454 | P07943 | Aldo-keto reductase family 1 member B1 | Akr1b1 | 4786 | nM | IC50 |
TKC005454 | P08684 | Cytochrome P450 3A4 | CYP3A4 | 15849 | nM | Potency |
TKC005454 | P22303 | Acetylcholinesterase | ACHE | >6410 | nM | Ki |
TKC005454 | P23141 | Liver carboxylesterase 1 | CES1 | 544 | nM | Ki |
TKC005454 | Q72874 | Protease | pol | 69600 | nM | IC50 |
TKC005454 | O75874 | Isocitrate dehydrogenase [NADP] cytoplasmic | IDH1 | 20596 | nM | Potency |
TKC005454 | O95398 | Rap guanine nucleotide exchange factor 3 | RAPGEF3 | 44668 | nM | Potency |
TKC005454 | P43220 | Glucagon-like peptide 1 receptor | GLP1R | 28184 | nM | Potency |
TKC005454 | P53350 | Serine/threonine-protein kinase PLK1 | PLK1 | 26680 | nM | Potency |
TKC005454 | P84022 | Mothers against decapentaplegic homolog 3 | SMAD3 | 4467 | nM | Potency |
TKC005454 | Q14191 | Werner syndrome ATP-dependent helicase | WRN | 56234 | nM | Potency |
TKC005454 | Q16236 | Nuclear factor erythroid 2-related factor 2 | NFE2L2 | 29093 | nM | Potency |
TKC005454 | O75164 | Lysine-specific demethylase 4A | KDM4A | 31623 | nM | Potency |
TKC005454 | P27695 | DNA-(apurinic or apyrimidinic site) endonuclease | APEX1 | 39811 | nM | Potency |
TKC005454 | Q962Y6 | Thioredoxin glutathione reductase | TGR | 3981 | nM | Potency |
TKC005454 | Q9UBT6 | DNA polymerase kappa | POLK | 19953 | nM | Potency |
TKC005454 | Q9UNA4 | DNA polymerase iota | POLI | 22387 | nM | Potency |
TKC005454 | P08183 | ATP-dependent translocase ABCB1 | ABCB1 | 50 | % | Inhibition |
TKC005454 | O75496 | Geminin | GMNN | 4110 | nM | Potency |
TKC005454 | O89049 | Thioredoxin reductase 1, cytoplasmic | Txnrd1 | 28184 | nM | Potency |
TKC005454 | O94782 | Ubiquitin carboxyl-terminal hydrolase 1 | USP1 | 79433 | nM | Potency |
TKC005454 | P39748 | Flap endonuclease 1 | FEN1 | 14125 | nM | Potency |
TKC005454 | P40763 | Signal transducer and activator of transcription 3 | STAT3 | 4600 | nM | IC50 |
TKC005454 | O42275 | Acetylcholinesterase | ache | 3 | % | Inhibition |
TKC005454 | P0DTD1 | Replicase polyprotein 1ab | rep | -10 | % | Inhibition |
TKC005454 | P81908 | Cholinesterase | BCHE | 12 | % | Inhibition |
TKC005454 | P83916 | Chromobox protein homolog 1 | CBX1 | 28184 | nM | Potency |
TKC005454 | P00784 | Papain | 89800 | nM | IC50 | |
TKC005454 | P0C6U8 | Replicase polyprotein 1a | 1a | 800 | nM | IC50 |
TKC005454 | Q01196 | Runt-related transcription factor 1 | RUNX1 | 12589 | nM | Potency |
TKC005454 | Q96KQ7 | Histone-lysine N-methyltransferase EHMT2 | EHMT2 | 7080 | nM | Potency |
TKC005454 | Q96QE3 | ATPase family AAA domain-containing protein 5 | ATAD5 | 16354 | nM | Potency |
TKC005454 | P08659 | Luciferin 4-monooxygenase | 21331 | nM | Potency | |
TKC005454 | P54132 | Bloom syndrome protein | BLM | 39811 | nM | Potency |
TKC005454 | Q6W5P4 | Neuropeptide S receptor | NPSR1 | 25119 | nM | Potency |
TKC005454 | B2RXH2 | Lysine-specific demethylase 4E | KDM4E | 35481 | nM | Potency |
TKC005454 | O00255 | Menin | MEN1 | 17783 | nM | Potency |
TKC005454 | O15296 | Polyunsaturated fatty acid lipoxygenase ALOX15B | ALOX15B | 25119 | nM | Potency |
TKC005454 | O97447 | Putative fructose-1,6-bisphosphate aldolase | fba | 1581 | nM | Potency |
TKC005454 | P02791 | Ferritin light chain | FTL | 35481 | nM | Potency |
TKC005454 | P15428 | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | HPGD | 19953 | nM | Potency |
TKC005454 | P25779 | Cruzipain | 39811 | nM | Potency | |
TKC005454 | P46063 | ATP-dependent DNA helicase Q1 | RECQL | 12589 | nM | Potency |
TKC005454 | P55210 | Caspase-7 | CASP7 | 25119 | nM | Potency |
TKC005454 | Q92830 | Histone acetyltransferase KAT2A | KAT2A | 28184 | nM | Potency |
TKC005454 | Q99714 | 3-hydroxyacyl-CoA dehydrogenase type-2 | HSD17B10 | 25119 | nM | Potency |
TKC005454 | Q9F4F7 | 4'-phosphopantetheinyl transferase ffp | ffp | 19953 | nM | Potency |
TKC005454 | O00748 | Cocaine esterase | CES2 | 141 | nM | Ki |
TKC005454 | O14746 | Telomerase reverse transcriptase | TERT | 75 | % | Inhibition |
TKC005454 | P06746 | DNA polymerase beta | POLB | 22387 | nM | Potency |
TKC005454 | P10520 | Streptokinase A | ska | 3953 | nM | EC50 |
TKC005454 | P10586 | Receptor-type tyrosine-protein phosphatase F | PTPRF | 36900 | nM | IC50 |
TKC005454 | P10828 | Thyroid hormone receptor beta | THRB | 50119 | nM | Potency |
TKC005454 | P29350 | Tyrosine-protein phosphatase non-receptor type 6 | PTPN6 | 39500 | nM | IC50 |
TKC005454 | P29990 | Genome polyprotein | 90060 | nM | IC50 | |
TKC005454 | P43378 | Tyrosine-protein phosphatase non-receptor type 9 | PTPN9 | 59400 | nM | IC50 |
TKC005454 | P49798 | Regulator of G-protein signaling 4 | RGS4 | 56234 | nM | Potency |
TKC005454 | Q03164 | Histone-lysine N-methyltransferase 2A | KMT2A | 31623 | nM | Potency |
TKC005454 | Q06124 | Tyrosine-protein phosphatase non-receptor type 11 | PTPN11 | 22500 | nM | IC50 |
TKC005454 | Q16665 | Hypoxia-inducible factor 1-alpha | HIF1A | 1360 | nM | IC50 |
TKC005454 | Q9NR56 | Muscleblind-like protein 1 | MBNL1 | 44668 | nM | Potency |
TKC005454 | Q9UIF8 | Bromodomain adjacent to zinc finger domain protein 2B | BAZ2B | 14125 | nM | Potency |
TKC005454 | Q9Y253 | DNA polymerase eta | POLH | 35481 | nM | Potency |
TKC005454 | Q9Y468 | Lethal(3)malignant brain tumor-like protein 1 | L3MBTL1 | 17783 | nM | Potency |
Uniport ID | Uniport Name | ICD-11 |
---|---|---|
P10636 | TAU_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P10636 | TAU_HUMAN | Alzheimer disease [ICD-11: 8A20] |
P10636 | TAU_HUMAN | Mild neurocognitive disorder [ICD-11: 6D71] |
P10636 | TAU_HUMAN | Choreiform disorder [ICD-11: 8A01] |
P10636 | TAU_HUMAN | Parkinsonism [ICD-11: 8A00] |
P10636 | TAU_HUMAN | Central nervous system disease [ICD-11: 8A04-8D87] |
P10636 | TAU_HUMAN | Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P11473 | VDR_HUMAN | Chronic kidney disease [ICD-11: GB61] |
P11473 | VDR_HUMAN | Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 | VDR_HUMAN | Hyper-parathyroidism [ICD-11: 5A51] |
P11473 | VDR_HUMAN | Hypo-parathyroidism [ICD-11: 5A50] |
P11473 | VDR_HUMAN | Mineral deficiency [ICD-11: 5B5K] |
P11473 | VDR_HUMAN | Psoriasis [ICD-11: EA90] |
P11473 | VDR_HUMAN | Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 | VDR_HUMAN | Low bone mass disorder [ICD-11: FB83] |
P11473 | VDR_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 | VDR_HUMAN | Prostate cancer [ICD-11: 2C82] |
P11473 | VDR_HUMAN | Prostate disease [ICD-11: GA91] |
P11473 | VDR_HUMAN | Abnormal micturition [ICD-11: MF50] |
P11473 | VDR_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 | VDR_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 | VDR_HUMAN | Acne vulgaris [ICD-11: ED80] |
P18031 | PTN1_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P18031 | PTN1_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P18031 | PTN1_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
P18031 | PTN1_HUMAN | Obesity [ICD-11: 5B80-5B81] |
P18031 | PTN1_HUMAN | Ophthalmic devices/implants/grafts injury [ICD-11: PK97] |
P18031 | PTN1_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P18031 | PTN1_HUMAN | Metabolic disorder [ICD-11: 5C50-5D2Z] |
P18031 | PTN1_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P08575 | PTPRC_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P08575 | PTPRC_HUMAN | Transplanted organ/tissue [ICD-11: QB63] |
P08575 | PTPRC_HUMAN | Leukaemia [ICD-11: 2A60-2B33] |
P08575 | PTPRC_HUMAN | Diffuse large B-cell lymphoma [ICD-11: 2A81] |
P08575 | PTPRC_HUMAN | Lymphoma [ICD-11: 2A80-2A86] |
P08575 | PTPRC_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P08575 | PTPRC_HUMAN | Transplant rejection [ICD-11: NE84] |
P08575 | PTPRC_HUMAN | Pain [ICD-11: MG30-MG3Z] |
P17706 | PTN2_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 | CP3A4_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08684 | CP3A4_HUMAN | Atopic eczema [ICD-11: EA80] |
P08684 | CP3A4_HUMAN | Anxiety disorder [ICD-11: 6B00-6B0Z] |
P22303 | ACES_HUMAN | Alzheimer disease [ICD-11: 8A20] |
P22303 | ACES_HUMAN | Glaucoma [ICD-11: 9C61] |
P22303 | ACES_HUMAN | Myasthenia gravis [ICD-11: 8C6Y] |
P22303 | ACES_HUMAN | Oesophageal/gastroduodenal disorder [ICD-11: DD90] |
P22303 | ACES_HUMAN | Pediculosis [ICD-11: 1G00] |
P22303 | ACES_HUMAN | Unspecific substance harmful effect [ICD-11: NE6Z] |
P22303 | ACES_HUMAN | Mild neurocognitive disorder [ICD-11: 6D71] |
P22303 | ACES_HUMAN | Parasitic worm infestation [ICD-11: 1F90] |
P22303 | ACES_HUMAN | Dementia [ICD-11: 6D80-6D8Z] |
P22303 | ACES_HUMAN | Pain [ICD-11: MG30-MG3Z] |
P22303 | ACES_HUMAN | Parkinsonism [ICD-11: 8A00] |
P22303 | ACES_HUMAN | Substance abuse [ICD-11: 6C40] |
P22303 | ACES_HUMAN | Lips/oral mucosa miscellaneous disorder [ICD-11: DA02] |
P22303 | ACES_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P22303 | ACES_HUMAN | Urinary system disease [ICD-11: GC2Z] |
P22303 | ACES_HUMAN | Neurodegenerative disorder [ICD-11: 8A20-8A23] |
P23141 | EST1_HUMAN | Peroxisomal disease [ICD-11: 5C57] |
P23141 | EST1_HUMAN | Synthesis disorder [ICD-11: 5C52-5C59] |
P23141 | EST1_HUMAN | Arterial occlusive disease [ICD-11: BD40] |
P23141 | EST1_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
P23141 | EST1_HUMAN | Mature B-cell lymphoma [ICD-11: 2A85] |
P23141 | EST1_HUMAN | Chronic arterial occlusive disease [ICD-11: BD4Z] |
O75874 | IDHC_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
O75874 | IDHC_HUMAN | Liver cancer [ICD-11: 2C12] |
O75874 | IDHC_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
O75874 | IDHC_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
O75874 | IDHC_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
O75874 | IDHC_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
O95398 | RPGF3_HUMAN | Epidermal dysplasias [ICD-11: EK90] |
P43220 | GLP1R_HUMAN | Cardiovascular disease [ICD-11: BA00-BE2Z] |
P43220 | GLP1R_HUMAN | Obesity [ICD-11: 5B80-5B81] |
P43220 | GLP1R_HUMAN | Type 2 diabetes mellitus [ICD-11: 5A11] |
P43220 | GLP1R_HUMAN | Type-1/2 diabete [ICD-11: 5A10-5A11] |
P43220 | GLP1R_HUMAN | Acute diabete complication [ICD-11: 5A2Y] |
P43220 | GLP1R_HUMAN | Diabetes mellitus [ICD-11: 5A10] |
P43220 | GLP1R_HUMAN | Dyspepsia [ICD-11: MD92] |
P43220 | GLP1R_HUMAN | Irritable bowel syndrome [ICD-11: DD91] |
P43220 | GLP1R_HUMAN | Intracranial injury [ICD-11: NA07] |
P43220 | GLP1R_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
P53350 | PLK1_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P53350 | PLK1_HUMAN | Myelodysplastic syndrome [ICD-11: 2A37] |
P53350 | PLK1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P53350 | PLK1_HUMAN | Prostate cancer [ICD-11: 2C82] |
P53350 | PLK1_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P53350 | PLK1_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
P53350 | PLK1_HUMAN | Lymphoma [ICD-11: 2A80-2A86] |
P53350 | PLK1_HUMAN | Nasopharyngeal cancer [ICD-11: 2B6B] |
P53350 | PLK1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P84022 | SMAD3_HUMAN | Herpes simplex infection [ICD-11: 1F00] |
P84022 | SMAD3_HUMAN | Kidney fibrosis [ICD-11: GC01] |
Q14191 | WRN_HUMAN | Mature T-cell lymphoma [ICD-11: 2A90] |
Q16236 | NF2L2_HUMAN | Ataxic disorder [ICD-11: 8A03] |
Q16236 | NF2L2_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 | NF2L2_HUMAN | Glaucoma [ICD-11: 9C61] |
Q16236 | NF2L2_HUMAN | Lung cancer [ICD-11: 2C25] |
Q16236 | NF2L2_HUMAN | Macular degeneration [ICD-11: 9B75] |
Q16236 | NF2L2_HUMAN | Melanoma [ICD-11: 2C30] |
Q16236 | NF2L2_HUMAN | Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 | NF2L2_HUMAN | Pulmonary hypertension [ICD-11: BB01] |
Q16236 | NF2L2_HUMAN | Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 | NF2L2_HUMAN | Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 | NF2L2_HUMAN | Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 | NF2L2_HUMAN | Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 | NF2L2_HUMAN | Motor neuron disease [ICD-11: 8B60] |
Q16236 | NF2L2_HUMAN | Multiple sclerosis [ICD-11: 8A40] |
P27695 | APEX1_HUMAN | Retinopathy [ICD-11: 9B71] |
P27695 | APEX1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P27695 | APEX1_HUMAN | Ocular cancer [ICD-11: 2D00-2D07] |
P27695 | APEX1_HUMAN | Brain cancer [ICD-11: 2A00] |
P27695 | APEX1_HUMAN | Melanoma [ICD-11: 2C30] |
P08183 | MDR1_HUMAN | Lung cancer [ICD-11: 2C25] |
P08183 | MDR1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P08183 | MDR1_HUMAN | Bacterial infection [ICD-11: 1A00-1C4Z] |
P08183 | MDR1_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
P08183 | MDR1_HUMAN | Adrenal cancer [ICD-11: 2D11] |
P08183 | MDR1_HUMAN | Ovarian cancer [ICD-11: 2C73] |
O94782 | UBP1_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P40763 | STAT3_HUMAN | Psoriasis [ICD-11: EA90] |
P40763 | STAT3_HUMAN | Brain cancer [ICD-11: 2A00] |
P40763 | STAT3_HUMAN | Colorectal cancer [ICD-11: 2B91] |
P40763 | STAT3_HUMAN | Liver cancer [ICD-11: 2C12] |
P40763 | STAT3_HUMAN | Malignant digestive organ neoplasm [ICD-11: 2C11] |
P40763 | STAT3_HUMAN | Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P40763 | STAT3_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
P40763 | STAT3_HUMAN | Respiratory infection [ICD-11: CA07-CA4Z] |
P40763 | STAT3_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P40763 | STAT3_HUMAN | Immune system disease [ICD-11: 4A01-4B41] |
P40763 | STAT3_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
P40763 | STAT3_HUMAN | Mature B-cell leukaemia [ICD-11: 2A82] |
P40763 | STAT3_HUMAN | Multiple myeloma [ICD-11: 2A83] |
P40763 | STAT3_HUMAN | Mycosis fungoides [ICD-11: 2B01] |
P40763 | STAT3_HUMAN | Ulcerative colitis [ICD-11: DD71] |
P40763 | STAT3_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q96KQ7 | EHMT2_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
Q96KQ7 | EHMT2_HUMAN | Postoperative inflammation [ICD-11: 1A00-CA43] |
Q96KQ7 | EHMT2_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P25779 | CYSP_TRYCR | Parasitic worm infestation [ICD-11: 1F90] |
P25779 | CYSP_TRYCR | Malaria [ICD-11: 1F40-1F45] |
P55210 | CASP7_HUMAN | Cystic fibrosis [ICD-11: CA25] |
O14746 | TERT_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
O14746 | TERT_HUMAN | Colorectal cancer [ICD-11: 2B91] |
O14746 | TERT_HUMAN | Liver cancer [ICD-11: 2C12] |
O14746 | TERT_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
O14746 | TERT_HUMAN | Pancreatic cancer [ICD-11: 2C10] |
O14746 | TERT_HUMAN | Breast cancer [ICD-11: 2C60-2C6Y] |
O14746 | TERT_HUMAN | Lung cancer [ICD-11: 2C25] |
O14746 | TERT_HUMAN | Multiple myeloma [ICD-11: 2A83] |
O14746 | TERT_HUMAN | Myelodysplastic syndrome [ICD-11: 2A37] |
O14746 | TERT_HUMAN | Myeloproliferative neoplasm [ICD-11: 2A20] |
O14746 | TERT_HUMAN | Thrombocytosis [ICD-11: 3B63] |
O14746 | TERT_HUMAN | Acute myeloid leukaemia [ICD-11: 2A60] |
O14746 | TERT_HUMAN | Melanoma [ICD-11: 2C30] |
O14746 | TERT_HUMAN | Ovarian cancer [ICD-11: 2C73] |
O14746 | TERT_HUMAN | Glaucoma [ICD-11: 9C61] |
O14746 | TERT_HUMAN | Head and neck cancer [ICD-11: 2D42] |
O14746 | TERT_HUMAN | Liver cancer [ICD-11: 2C12] |
O14746 | TERT_HUMAN | Brain cancer [ICD-11: 2A00] |
O14746 | TERT_HUMAN | Prostate cancer [ICD-11: 2C82] |
O14746 | TERT_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P06746 | DPOLB_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10828 | THB_HUMAN | Hyper-lipoproteinaemia [ICD-11: 5C80] |
P10828 | THB_HUMAN | Hypo-thyroidism [ICD-11: 5A00] |
P10828 | THB_HUMAN | Inborn lipid metabolism error [ICD-11: 5C52] |
P10828 | THB_HUMAN | Skin postprocedural disorder [ICD-11: EL8Y] |
P10828 | THB_HUMAN | Thyrotoxicosis [ICD-11: 5A02] |
Q06124 | PTN11_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16665 | HIF1A_HUMAN | Adrenomedullary hyperfunction [ICD-11: 5A75] |
Q16665 | HIF1A_HUMAN | Brain cancer [ICD-11: 2A00] |
Q16665 | HIF1A_HUMAN | Lymphoma [ICD-11: 2A80-2A86] |
Q16665 | HIF1A_HUMAN | Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16665 | HIF1A_HUMAN | Pulmonary hypertension [ICD-11: BB01] |